AI-Enabled Drug Discovery Platforms Navigating the Confluence of Software Medical Device and Pharmac
1Euclid University
2YILDIZ TEKNİK ÜNİVERSİTESİ
3İSTANBUL TİCARET ÜNİVERSİTESİ
Yildiz Social Science Review 2026, Vol. 12, Issue 1, pp. 40-54; doi.org/10.51803/yssr.1937910
Abstract
The integration of artificial intelligence into drug discovery platforms presents a fundamental challenge to established regulatory taxonomies worldwide, raising a deceptively simple question with profound implications: Should AI-enabled drug discovery platforms be regulated as software, as medical devices, or as pharmaceuticals? This article examines this regulatory trilemma through the dual lens of comparative global frameworks and Sino-African trade relations. The analysis reveals that major jurisdictions—including the United States, European Union, and China—have adopted hybrid approaches that defy simple categorization, with the FDA emphasizing Predetermined Change Control Plans for adaptive algorithms, the EU layering AI Act requirements atop Medical Device Regulation frameworks, and China advancing a specialized AI medical device guidance architecture. For African regulatory environments, where the African Medicines Agency is newly operational and most National Regulatory Authorities function at WHO Maturity Level 3, this global fragmentation presents both peril and opportunity. The article argues that China's emergence as a leading developer of AI-enabled drug discovery technologies, combined with its deepening pharmaceutical trade relationships across Africa under FOCAC frameworks, creates unprecedented possibilities for regulatory leapfrogging through Sino-African cooperation. By examining trade patterns, investment flows, and capacity-building initiatives, this research demonstrates that the regulatory classification question is not merely a technical matter of legal taxonomy but a strategic determinant of market access, technology transfer, and ultimately, health equity across the African continent. The article concludes with concrete recommendations for harmonized approaches, South-South regulatory cooperation mechanisms, and African-specific adaptation of global AI governance principles.
References
- Abdulwahab, A. A., Okafor, U. G., Adesuyi, D. S., Miranda, A. V., Yusuf, R. O., & Eliseo Lucero-Prisno, D. (2024). The African Medicines Agency and medicines regulation: Progress, challenges, and recommendations. Health Care Science, 3(5), 350–359. [CrossRef]
- African Union. (2014). African Union convention on cyber security and personal data protection. African Union.
- Aniche, E. T. (2023). African continental free trade area and african union agenda 2063: The roads to Addis Ababa and Kigali. Journal of Contemporary African Studies, 41(4), 377–392. [CrossRef]
- Atacan, C., & Açık, A. (2023). Impact of geopolitical risk on international trade: Evidence from container throughputs. Transactions on Maritime Science, 12(2). [CrossRef]
- Cerf, M. E. (2018). The Sustainable Development Goals: Contextualizing Africa's economic and health landscape. Global Challenges, 2(8), 1800014. [CrossRef]
- Daneshjou, R., Smith, M. P., Sun, M. D., Rotemberg, V., & Zou, J. (2021). Lack of transparency and potential bias in artificial intelligence data sets and algorithms: A scoping review. JAMA Dermatology, 157(11), 1362–1369. [CrossRef]
- de Villiers, K. (2021). Bridging the health inequality gap: An examination of South Africa's social innovation in health landscape. Infectious Diseases of Poverty, 10, 19. [CrossRef]
- European Parliament & Council of the European Union. (2024). Regulation (EU) 2024/1689 of the European Parliament and of the Council laying down harmonised rules on artificial intelligence (Artificial Intelligence Act). https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32024R1689 Accessed on Jun 08, 2026.
- Ibáñez Antolín, A. (2021). Applications of machine learning in drug discovery and development. Proceedings of MOL2NET'21. Conference on Molecular, Biomedical & Computational Sciences and Engineering (7th ed.). USE.DAT- 07: USA-Europe Data Analysis Trends Congress, Cambridge, UK-Bilbao, Basque Country-Miami, USA, 2021. [CrossRef]
- International Medical Device Regulators Working Group. (2022). Machine learning-enabled medical devices: Key terms and definitions [IMDRF/AIMD WG/N67FINAL:2022]. International Medical Device Regulators Forum.
- Li, P., Williams, R., Gilbert, S., & Anderson, S. (2023). Regulating artificial intelligence and machine learning-enabled medical devices in Europe and the United Kingdom. Law, Technology and Humans, 5(2), 94–113. [CrossRef]
- Lognoul, M. (2025). Regulation
- (EU) 2024/1689 laying down harmonised rules on artificial intelligence (Artificial Intelligence Act-AI Act). Revue du Droit des Technologies de l'Information, 3-4, 145-189.
- Muehlematter, U. J., Daniore, P., & Vokinger, K. N. (2021). Approval of artificial intelligence and machine learning- based medical devices in the USA and Europe (2015–2020): A comparative analysis. The Lancet Digital Health, 3(3), e195–e203. [CrossRef] Ncube, C. B. (2015). Intellectual property policy, law and administration in Africa: Exploring continental and sub- regional co-operation. Routledge. [CrossRef]
- Niyungeko, G. (Ed.) (2019). Treaty for the establishment of the African Medicines Agency. In African Yearbook of International Law Online / Annuaire Africain de Droit International Online. 24(1), 396–415. [CrossRef]
- Nwauche, E. S. (2018). Intellectual property policy, law and administration in Africa: Exploring continental and sub- regional cooperation. South African Intellectual Property Law Journal, 6(1), 120–123.
- Obunike, C. L., & Nwakob, C. B. (2025). The role of intellectual property in the African continental free trade area: Opportunities and challenges. Chukwuemeka Odumegwu Ojukwu University Journal of Commercial and Property Law, 5(1).
- Rosen, K. L., & Mandl, K. D. (2025). Regulating flexibility for artificial intelligence: FDA experience with predetermined change control plans [Preprint]. medRxiv doi: 10.1101/2025.08.26.25334477 [CrossRef]
- United Nations Conference on Trade and Development. (2026). Pharmaceutical trade flows between China and Africa: Trends, projections, and policy implications. United Nations Conference on Trade and Development.
- Vieira, M., Andia, T., Karim, O., Srishti, S. A., Pineda, S. A., Alonso Ruiz, A., Large, K., Liu, Y., Moon, S., & Naher, N. (2023). Rising pharmaceutical innovation in the Global South: A landscape study. Journal of Pharmaceutical Policy and Practice, 16(1), 155. [CrossRef]
- Zhang, L., & Yan, J. (2026). Approval of AI-based medical devices in China from 2020 to 2025: Retrospective analysis. JMIR Medical Informatics, 14, e85538. [CrossRef]
Share and Cite
KATTERBAUER, K.; YILMAZ, S.; ÖZBAY, R.D. AI-Enabled Drug Discovery Platforms Navigating the Confluence of Software Medical Device and Pharmac. Yildiz Social Science Review 2026, Vol. 12, pp. 40-54. https://doi.org/10.51803/yssr.1937910
Export: